RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.

J Transl Med · 2022 · PMC9441062 · PMID 36059009

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

close to significanceno p-value reported

We then performed multivariate analysis using these three features, and we discovered that they were no longer statistically significant, with bypass mutations and RB1 and TP53 co-mutations being close to significance.

also in 2,130 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.